Skip to content
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
    • Investor Contact
  • News & Media
    • News
  • Healthcare Professionals
  • Careers
    • Life at Acadia
    • Why Work At Acadia
    • Acadia Job Listings
Important Note
This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored publications below may contain information about doses, uses, formulations and populations different from product labelling or contain information about investigational compounds or uses not approved by the FDA.

I certify that I am a licensed health care provider in the U.S.
YES
NO
Important Note
You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

YES
NO
Acadia logo

Acadia Pharmaceuticals

  • About
    About
    Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most.
    Learn More
    • Acadia Leadership Team
    • History
    • Corporate Social Responsibility
    • Diversity, Equity & Inclusion (DE&I)
    • Strategic Partnerships
    • Corporate Sponsorships
    • Scholarship
  • Our Medicines
    Our Medicines
    Learn more about our FDA-approved treatments.
    • NUPLAZID® (pimavanserin)
    • DAYBUE™ (trofinetide)
  • Pipeline
    Pipeline
    We are driven to develop innovative and novel medicines to help address unmet medical needs and to elevate life through science.
    • Product Pipeline
    • Clinical Trials
  • Therapeutic Areas
    Therapeutic Areas
    At Acadia, we see promise in therapeutic areas where the unmet need remains high.
    Learn More
    • Parkinson’s Disease Psychosis
    • Rett Syndrome
    • Negative Symptoms of Schizophrenia
    • Prader-Willi Syndrome
    • Alzheimer’s Disease Psychosis
  • Patients
  • Perspectives
  • About Acadia
    Back
    About Acadia
    • Acadia Leadership Team
    • History
    • Corporate Social Responsibility
    • Diversity, Equity & Inclusion (DE&I)
    • Corporate Sponsorships
    • Strategic Partnerships
    • Scholarship
  • Our Medicine
    Back
    Our Medicine
    • Nuplazid® (pimavanserin)
    • Daybue™ (trofinetide)
  • Product Pipeline
  • Therapeutic Areas
    Back
    Therapeutic Areas
    • Parkinson’s Disease Psychosis
    • Rett Syndrome
    • Negative Symptoms of Schizophrenia
    • Prader-Willi Syndrome
    • Alzheimer’s Disease Psychosis
  • Patients
  • Acadia Perspectives
  • Investors
    Back
    Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
    • Investor Contact
  • News & Media
    Back
    News & Media
    • News
  • Healthcare Professionals
  • Acadia Careers
    Back
    Acadia Careers
    • Life at Acadia
    • Why Work At Acadia
    • Acadia Job Listings
Home › Rett Syndrome

Acadia logo

© 2023 Acadia Pharmaceuticals Inc. All rights reserved.

  • Privacy Policy
  • Data Privacy Framework Notice
  • Compliance Policy
  • Accessibility
  • Community Guidelines
  • Contact Us
  • LinkedIn
  • Twitter
  • Sitemap
  • Terms of Use
  • Cookies Policy